Found: 1047
Select item for more details and to access through your institution.
Impact of Dapagliflozin Adjunctive Therapy on the Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes and Chronic Kidney Disease Stages 2-5: A systematic review and meta-analysis.
- Published in:
- Sultan Qaboos University Medical Journal, 2024, v. 24, n. 3, p. 317, doi. 10.18295/SQUMJ.12.2023.093
- By:
- Publication type:
- Article
SGLT2 Inhibitor Dapagliflozin Increases Skeletal Muscle and Brain Fatty Acid Uptake in Individuals With Type 2 Diabetes: A Randomized Double-Blind Placebo-Controlled Positron Emission Tomography Study.
- Published in:
- Diabetes Care, 2024, v. 47, n. 9, p. 1630, doi. 10.2337/dc24-0470
- By:
- Publication type:
- Article
Dapagliflozin Reduces Adverse Renal and Cardiovascular Events in Patients With Chronic Kidney Disease.
- Published in:
- Journal of Clinical Outcomes Management, 2020, v. 27, n. 6, p. 248, doi. 10.12788/jcom.0030
- By:
- Publication type:
- Article
Dapagliflozin Improves Cardiovascular Outcomes in Patients With Heart Failure and Reduced Ejection Fraction.
- Published in:
- Journal of Clinical Outcomes Management, 2020, v. 27, n. 4, p. 159
- By:
- Publication type:
- Article
Quality Measure Attainment After Add-on Therapy of Both Saxagliptin and Dapagliflozin to Metf ormin versus Single Add-on of Saxagliptin or Dapagliflozin.
- Published in:
- Journal of Clinical Outcomes Management, 2016, v. 23, n. 9, p. 407
- By:
- Publication type:
- Article
New pharmacological approaches to diabetes management.
- Published in:
- Practice Nursing, 2015, v. 26, n. 3, p. 140, doi. 10.12968/pnur.2015.26.3.140
- By:
- Publication type:
- Article
Value of SGLT-2 inhibitors in the treatment of chronic kidney disease: Clinical and practical implications.
- Published in:
- Wiener Klinische Wochenschrift, 2023, v. 135, n. 3/4, p. 97, doi. 10.1007/s00508-022-02096-x
- By:
- Publication type:
- Article
Dapagliflozin for inpatient hyperglycemia in cardiac surgery patients with type 2 diabetes: randomised controlled trial (Dapa-Hospital trial).
- Published in:
- Acta Diabetologica, 2023, v. 60, n. 11, p. 1481, doi. 10.1007/s00592-023-02138-4
- By:
- Publication type:
- Article
DAPAGLIFLOZIN TRANSDERMAL SYSTEM TTS MTC-D DEVELOPED BY BIOTTS S.A. IN THE RELATIVE BIOAVAILABILITY CLINICAL STUDY COMPARING TRANSDERMAL SYSTEM WITH THE DAPAGLIFLOZIN TABLETS IN HEALTHY SUBJECTS.
- Published in:
- Medical Science Pulse, 2024, v. 18, p. 85
- By:
- Publication type:
- Article
IN VIVO EVALUATION OF OPTIMIZED FORMULATION OF DAPAGLIFLOZIN AND SAXAGLIPTIN BILAYERED TABLETS.
- Published in:
- Indian Drugs, 2024, v. 61, n. 3, p. 56, doi. 10.53879/id.61.03.14209
- By:
- Publication type:
- Article
EFFICACY AND SAFETY OF DIPEPTIDYL PEPTIDASE-4 INHIBITOR COMPARED TO SULPHONYLUREA IN TYPE II DIABETES PATIENTS INADEQUATELY CONTROLLED WITH METFORMIN ALONE.
- Published in:
- Journal of Universal College of Medical Sciences, 2022, v. 10, n. 1, p. 40, doi. 10.3126/jucms.v10i01.47228
- By:
- Publication type:
- Article
Effect of Dapagliflozin on Exercise Capacity and Cardiovascular Risk in Patients with Heart Failure.
- Published in:
- Healthcare (2227-9032), 2022, v. 10, n. 11, p. 2133, doi. 10.3390/healthcare10112133
- By:
- Publication type:
- Article
Clinical Parameters Affecting the Therapeutic Efficacy of SGLT-2—Comparative Effectiveness and Safety of Dapagliflozin and Empagliflozin in Patients with Type 2 Diabetes.
- Published in:
- Healthcare (2227-9032), 2022, v. 10, n. 7, p. 1153, doi. 10.3390/healthcare10071153
- By:
- Publication type:
- Article
The effects of dapagliflozin on serum electrolytes concentration in adult male rats.
- Published in:
- Kufa Journal for Veterinary Medical Sciences, 2018, v. 9, n. 2, p. 55
- By:
- Publication type:
- Article
Qualitative and Quantitative Determination of Dapagliflozin Propanediol Monohydrate and Its Related Substances and Degradation Products Using LCMS and Preparative Chromatography Methods.
- Published in:
- Baghdad Science Journal, 2023, v. 20, p. 1901, doi. 10.21123/bsj.2023.7596
- By:
- Publication type:
- Article
Comparative Genitourinary Safety of In-class Sodium-Glucose Cotransporter-2 Inhibitors among Patients with Heart Failure with Preserved Ejection Fraction: A Cohort Study.
- Published in:
- American Journal of Cardiovascular Drugs, 2024, v. 24, n. 3, p. 455, doi. 10.1007/s40256-024-00648-2
- By:
- Publication type:
- Article
Eligibility and Cost-Utility Analysis of Dapagliflozin in Patients with Heart Failure Across the Whole Spectrum of Ejection Fraction in South Korea.
- Published in:
- American Journal of Cardiovascular Drugs, 2024, v. 24, n. 2, p. 313, doi. 10.1007/s40256-024-00632-w
- By:
- Publication type:
- Article
Practical Guidance for the Use of SGLT2 Inhibitors in Heart Failure.
- Published in:
- American Journal of Cardiovascular Drugs, 2023, v. 23, n. 6, p. 609, doi. 10.1007/s40256-023-00601-9
- By:
- Publication type:
- Article
Effect of Dapagliflozin Versus Empagliflozin on Cardiovascular Death in Patients with Heart Failure Across the Spectrum of Ejection Fraction: Cost per Outcome Analysis.
- Published in:
- American Journal of Cardiovascular Drugs, 2023, v. 23, n. 3, p. 323, doi. 10.1007/s40256-023-00578-5
- By:
- Publication type:
- Article
Cost Effectiveness of Adding Dapagliflozin to Standard Care in Heart Failure Patients with Reduced Ejection Fraction: A Systematic Review.
- Published in:
- American Journal of Cardiovascular Drugs, 2023, v. 23, n. 2, p. 127, doi. 10.1007/s40256-022-00564-3
- By:
- Publication type:
- Article
Dapagliflozin Versus Sacubitril–Valsartan to Improve Outcomes of Patients with Reduced Ejection Fraction and Diabetes Mellitus.
- Published in:
- American Journal of Cardiovascular Drugs, 2022, v. 22, n. 3, p. 325, doi. 10.1007/s40256-021-00506-5
- By:
- Publication type:
- Article
Correction to: Dapaglifozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction.
- Published in:
- American Journal of Cardiovascular Drugs, 2021, v. 21, n. 6, p. 701, doi. 10.1007/s40256-021-00503-8
- By:
- Publication type:
- Article
Effects of Dapagliflozin on Cardiovascular Events, Death, and Safety Outcomes in Patients with Heart Failure: A Meta-Analysis.
- Published in:
- American Journal of Cardiovascular Drugs, 2021, v. 21, n. 3, p. 321, doi. 10.1007/s40256-020-00441-x
- By:
- Publication type:
- Article
DAPA-HF: Dapagliflozin Reduced the Risk of Total (First and Repeat) Heart Failure (HF) Hospitalizations and Cardiovascular (CV) Death / Time-To-First Event Analysis Underestimated the Benefit of Dapagliflozin in HF and Reduced Ejection Fraction (HFrEF).
- Published in:
- Rhythmos, 2021, v. 16, n. 3, p. 68
- By:
- Publication type:
- Article
DAPA-HF: Baseline Kidney Function did not Modify the Benefits of Dapagliflozin on Morbidity & Mortality in HFrEF, and Dapagliflozin Slowed the Rate of Decline in eGFR, Including in Patients Without Diabetes.
- Published in:
- Rhythmos, 2021, v. 16, n. 2, p. 46
- By:
- Publication type:
- Article
DAPA-HF: Dapagliflozin Reduced the Risk of Death and Worsening Heart Failure and Improved Symptoms Across the Broad Spectrum of Age Studied in DAPA-HF.
- Published in:
- Rhythmos, 2020, v. 15, n. 2, p. 37
- By:
- Publication type:
- Article
DAPA-HF: Dapagliflozin Reduced CV Death and Worsening Heart Failure (HF), Improved Symptoms, Physical Function, and Quality of Life.
- Published in:
- Rhythmos, 2020, v. 15, n. 2, p. 37
- By:
- Publication type:
- Article
DECLARE-TIMI 58: In Patients With Type 2 Diabetes Who Had or Were at Risk for Atherosclerotic Cardiovascular (CV) Disease (CVD), Treatment With Dapagliflozin did not Change MACE Rate vs Placebo But Did Result in a Lower Rate of CV Death or Heart Failure (HF) Hospitalization, Reflecting a Lower Rate of HF Hospitalization
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 41
- By:
- Publication type:
- Article
ODYSSEY Outcomes: The Price of Alirocumab Would Have to be Reduced Drastically to be Cost-Effective.
- Published in:
- Rhythmos, 2019, v. 14, n. 2, p. 40
- By:
- Publication type:
- Article
Empagliflozin and Dapagliflozin Increase Na + and Inward Rectifier K + Current Densities in Human Cardiomyocytes Derived from Induced Pluripotent Stem Cells (hiPSC-CMs).
- Published in:
- Cells (2073-4409), 2022, v. 11, n. 23, p. 3707, doi. 10.3390/cells11233707
- By:
- Publication type:
- Article
Dapagliflozin Restores Impaired Autophagy and Suppresses Inflammation in High Glucose-Treated HK-2 Cells.
- Published in:
- Cells (2073-4409), 2021, v. 10, n. 6, p. 1457, doi. 10.3390/cells10061457
- By:
- Publication type:
- Article
Efficacy and safety of sodium–glucose co‐transporter‐2 inhibitors in kidney transplant recipients with diabetes mellitus.
- Published in:
- Diabetic Medicine, 2024, v. 41, n. 8, p. 1, doi. 10.1111/dme.15383
- By:
- Publication type:
- Article
Dapagliflozin improves erectile dysfunction in patients with type 2 diabetes mellitus: An open‐label, non‐randomized pilot study.
- Published in:
- Diabetic Medicine, 2024, v. 41, n. 1, p. 1, doi. 10.1111/dme.15217
- By:
- Publication type:
- Article
Implementation of dapagliflozin as adjunctive therapy in type 1 diabetes: A single centre real‐world experience.
- Published in:
- 2022
- By:
- Publication type:
- Letter to the Editor
The change in glycaemic control immediately after COVID‐19 vaccination in people with type 1 diabetes.
- Published in:
- Diabetic Medicine, 2022, v. 39, n. 4, p. 1, doi. 10.1111/dme.14774
- By:
- Publication type:
- Article
Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney disease.
- Published in:
- Diabetic Medicine, 2022, v. 39, n. 4, p. 1, doi. 10.1111/dme.14769
- By:
- Publication type:
- Article
The cost‐effectiveness of dapagliflozin compared to DPP‐4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands.
- Published in:
- Diabetic Medicine, 2021, v. 38, n. 4, p. 1, doi. 10.1111/dme.14371
- By:
- Publication type:
- Article
Association of British Clinical Diabetologists (ABCD) and Diabetes UK joint position statement and recommendations on the use of sodium–glucose cotransporter inhibitors with insulin for treatment of type 1 diabetes (Updated October 2020).
- Published in:
- Diabetic Medicine, 2021, v. 38, n. 2, p. 1, doi. 10.1111/dme.14458
- By:
- Publication type:
- Article
Renal outcomes with the newer antidiabetes drugs: the era before and after CREDENCE.
- Published in:
- Diabetic Medicine, 2020, v. 37, n. 4, p. 593, doi. 10.1111/dme.14262
- By:
- Publication type:
- Article
News and Views: Update on technologies, medicines and treatments.
- Published in:
- Diabetic Medicine, 2019, v. 36, n. 7, p. 913, doi. 10.1111/dme.13965
- By:
- Publication type:
- Article
SGLT2 inhibitors in Type 1 diabetes: is this the future?
- Published in:
- Diabetic Medicine, 2018, v. 35, n. 12, p. 1642, doi. 10.1111/dme.13791
- By:
- Publication type:
- Article
Clinical care and other categories posters: new technology, therapies and treatment.
- Published in:
- Diabetic Medicine, 2016, v. 33, p. 163, doi. 10.1111/dme.45_13048
- Publication type:
- Article
Clinical care and other categories posters: audit.
- Published in:
- Diabetic Medicine, 2016, v. 33, p. 87, doi. 10.1111/dme.23_13048
- Publication type:
- Article
The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus.
- Published in:
- Diabetic Medicine, 2015, v. 32, n. 7, p. 890, doi. 10.1111/dme.12772
- By:
- Publication type:
- Article
Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial.
- Published in:
- Diabetic Medicine, 2015, v. 32, n. 4, p. 531, doi. 10.1111/dme.12624
- By:
- Publication type:
- Article
Sotagliflozin versus dapagliflozin to improve outcome of patients with diabetes and worsening heart failure: a cost per outcome analysis.
- Published in:
- Frontiers in Pharmacology, 2024, p. 1, doi. 10.3389/fphar.2024.1373314
- By:
- Publication type:
- Article
Dapagliflozin versus sacubitril-valsartan for heart failure with mildly reduced or preserved ejection fraction.
- Published in:
- Frontiers in Pharmacology, 2024, p. 1, doi. 10.3389/fphar.2024.1357673
- By:
- Publication type:
- Article
Adverse event comparison between glucagon‐like peptide‐1 receptor agonists and other antiobesity medications following bariatric surgery.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 9, p. 3906, doi. 10.1111/dom.15737
- By:
- Publication type:
- Article
Efficacy and tolerability of initial triple combination therapy with metformin, dapagliflozin and saxagliptin compared with stepwise add‐on therapy in drug‐naïve patients with type 2 diabetes (TRIPLE‐AXEL study): A multicentre, randomized, 104‐week, open‐label, active‐controlled trial
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 9, p. 3642, doi. 10.1111/dom.15705
- By:
- Publication type:
- Article